



[Go to Product page](#)

Datasheet for ABIN7538069

Recombinant anti-NKG2A (Monalizumab Biosimilar) antibody

Overview

Quantity:	100 µg
Target:	NKG2A (Monalizumab Biosimilar)
Reactivity:	Human
Host:	Humanized
Antibody Type:	Recombinant Antibody
Clonality:	Monoclonal
Conjugate:	This NKG2A (Monalizumab Biosimilar) antibody is un-conjugated
Application:	ELISA, Western Blotting (WB)

Product Details

Purpose:	Monalizumab Biosimilar - Anti-KLRC1, NKG2A, CD159a, CD94 mAb - Research Grade
Isotype:	IgG4
Characteristics:	Antibody Type: IgG4-kappa
Purity:	> 85%
Grade:	Research Grade

Target Details

Target:	NKG2A (Monalizumab Biosimilar)
Background:	Monalizumab is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby

Target Details

promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).

CAS-No: 1228763-95-8

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS buffer PH7.5

Storage: -80 °C

Storage Comment: store at -80°C